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Conclusions: After L-Dopa administration a marked increase of rCBF in all brain regions occurs without a concomitant increase of the oxygen utilisation. Domperidone, a peripheral dopaminergic receptor antagonist, prevents this effect, without affecting the positive clinical influence of L-Dopa. These results indicate that L-Dopa affects the rCBF via a direct effect on the blood vessel wall and not indirect via a primary increase in oxygen metabolism. Also the rise in rCBF has no direct relation with the clinical improvement of the patients. A combination of the inhibition of cholesterol cleavage, Ilghydroxylation and possibly 17a-hydroxylation may explain why cortisol synthesis is more effectively inhibited than other steroids. These results are consistent with the view that etomidate directly inhibits steroid synthesis not by interfering with the mechanism of ACTH action but by blocking certain steroidogenic enzymes.
It may interfere with various cytochrome P450-dependent reactions as has been suggested for ketoconazole, an antimycotic drug which structurally resembles etomidate (Loose et al, 1983 We have reported (Young et al. Br Med J 1983; 286: 1691 -1693 ) abnormal regulation of prolactin (Prl) and other anterior pituitary hormones in cyclical oedema suggesting a hypothalamic disturbance may be present. Bromocriptine, a dopamine agonist which suppresses Prl secretion is known to be effective in some women with cyclical oedema and it is possible that the hypothalamic disturbance includes a reduction in dopaminergic activity. Pergolide mesylate is a new, potent and long acting dopamine agocist and is a potentially effective treatment for cyclical oedema. We have studied the acute effects of a single dose of this drug on plasma Prl concentrations in 8 women with cyclical oedema and 4 female controls.
Two patients (pts.) received 50 pgn pergolide and plasma Prl was suppressed throughout a 27 h study period but both pts. developed severe hypotension and nausea. A further 6 pts. (mean age 37.5 t 4 y) and 4 controls (mean age 26.5 t 2 y) received 10 I.LS~ pergolide and this dose
